Institutional Ownership
Arrivent Biopharma Inc
CUSIP 04272N102COMAVBPQ1 2026
13D / 13G Filings
23
Schedule 13D/13G on record
Beneficial Filers
14
Distinct reporting persons
Largest Stake
13.4%
Max % of class reported
Institutional Holders
132
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
23 filings · latest Mar 5, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 5, 2026 | Sofinnova Venture Partners Xi, L.P. ("Svp Xi") | 13G/A | 11.0% | 1.70M | SEC |
| 2 | Feb 17, 2026 | Infinitum Asset Management, LLC | 13G/A | 9.9% | — | SEC |
| 3 | Feb 17, 2026 | Hillhouse Investment Management, Ltd. | 13G/A | 9.5% | 3.93M | SEC |
| 4 | Jan 30, 2026 | The Vanguard Group | 13G/A | 4.5% | 1.87M | SEC |
| 5 | Jan 21, 2026 | Blackrock, Inc. | 13G | 5.6% | 2.32M | SEC |
| 6 | Nov 14, 2025 | Octagon Capital Advisors LP | 13G/A | 4.9% | 1.97M | SEC |
| 7 | Nov 5, 2025 | Fmr LLC | 13G/A | 8.4% | 3.41M | SEC |
| 8 | Oct 30, 2025 | The Vanguard Group | 13G | 5.0% | 2.03M | SEC |
| 9 | Oct 17, 2025 | Blackrock, Inc. | 13G/A | 4.9% | 2.01M | SEC |
| 10 | Oct 15, 2025 | Hbm Healthcare Investments (Cayman) Ltd. | 13G | 5.4% | 2.20M | SEC |
13 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Arrivent Biopharma Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 4.40M | $101.53M |
| 2 | Infinitum Asset Management, LLC | 4.15M | $95.72M |
| 3 | Hhlr Advisors, Ltd. | 3.93M | $90.64M |
| 4 | Orbimed Advisors LLC | 3.03M | $69.84M |
| 5 | Fmr LLC | 3.02M | $69.58M |
| 6 | Blackrock, Inc. | 2.53M | $58.37M |
| 7 | Octagon Capital Advisors LP | 1.97M | $45.47M |
| 8 | Novo Holdings A/S | 1.94M | $44.81M |
| 9 | Sofinnova Investments, Inc. | 1.70M | $39.14M |
| 10 | General Catalyst Group Management, LLC | 1.49M | $34.48M |